Naltrexone, a specific opiate receptor antagonist, is used clinically
in the treatment of heroin addiction and more recently, for the treatm
ent of dyskinesia associated with Huntington's disease (HD). Naltrexon
e may act as a potential hepatotoxin, as reflected in the elevation of
transaminase levels. However, one study concluded that, for a brief t
reatment period of 12 weeks, there is no contraindication to naltrexon
e treatment based solely on increased hepatic enzyme values. This stud
y monitored liver transaminase levels, in ten HD patients receiving da
ily doses, between 50 mg/day and 300 mg/day, of naltrexone for periods
of 10 to 36 months. Serum glutamic oxalacetic transaminase (SGOT) and
serum glutamic pyruvic transaminase (SGPT) levels were obtained befor
e treatment and at intervals of 1 to 4 months during treatment. Only o
ne of the ten patients treated with naltrexone had increased levels of
both SGOT and SGPT, whereas one other patient showed elevated levels
of SGPT. These elevations, which initially appeared dose related decre
ased to normal limits with continued treatment. Because many of the pa
tients were receiving other medications, a combination of drugs with n
altrexone may contribute to the increased transaminase levels seen in
two of the patients. In summary, chronic administration of naltrexone
in doses up to 300 mg/day for periods up to 36 months does not signifi
cantly change hepatic function, as measured by SGOT and SGPT levels.